Home › Trials › NCT07136012

Olpasiran to prevent a first major coronary event in people with high Lp(a)

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)

Phase 3 Interventional Amgen · NCT07136012

This trial tests whether olpasiran can lower the chance of a first heart attack, death from coronary heart disease, or urgent coronary revascularization in people age 50 and older with very high lipoprotein(a).

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment11000 (estimated)
Ages50 Years to 105 Years
SexAll
SponsorAmgen Industry-sponsored
Locations244 sites (Alexander City, Alabama and 243 other locations)
Trial IDNCT07136012 on ClinicalTrials.gov

What this trial studies

This Phase 3 interventional trial randomizes people with elevated Lp(a) and multiple cardiovascular risk factors or evidence of atherosclerosis to receive olpasiran or placebo and follows them for a first major coronary event (CHD death, myocardial infarction, or urgent coronary revascularization). Eligible participants are age 50 or older with Lp(a) ≥200 nmol/L and no prior acute atherothrombotic events or planned arterial revascularization. The study compares event rates between the olpasiran and placebo groups to determine whether lowering Lp(a) translates into fewer first major coronary events. The trial is conducted at U.S. clinical sites including centers in Alabama.

Who should consider this trial

Good fit: Ideal candidates are adults age 50 or older with Lp(a) ≥200 nmol/L who have multiple atherosclerotic cardiovascular risk factors or evidence of atherosclerosis but no prior heart attack, stroke, or revascularization and no major bleeding disorder.

Not a fit: People with prior atherothrombotic events, prior or planned arterial revascularization, major bleeding disorders, or normal/low Lp(a) are unlikely to benefit from this trial's intervention or are excluded.

Why it matters

Potential benefit: If successful, olpasiran could reduce the risk of a first major coronary event in people with markedly elevated Lp(a).

How similar studies have performed: Earlier olpasiran trials have shown large and sustained reductions in Lp(a) levels, but cardiovascular outcome benefit has not yet been proven in completed outcome trials.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age ≥50 years
* Lp(a)≥ 200 nmol/L during screening
* Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis

Exclusion Criteria:

* Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
* Prior or planned arterial revascularization
* History of major bleeding disorder

Where this trial is running

Alexander City, Alabama and 243 other locations

+194 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Cardiovascular DiseaseOlpasiranAMG 890Coronary heart diseaseCHDMyocardial infarctionCoronary revascularization
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.